New treatment options for generalized myasthenia gravis
Myasthenia gravis is an autoimmune disease in which autoantibodies against the postsynaptic membrane proteins of the neuromuscular junction disrupt impulse transmission thus causing pathological muscle weakness and fatigue that worsens throughout the day. Although the disease is not yet curable, mos...
Saved in:
Main Authors: | Antanas Vaitkus, J. Čiauškaitė, M. Malakauskaitė, M. Baublytė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2024-02-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/34581 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Case report: Efgartigimod is a novel therapeutic option for ocular myasthenia gravis: a report of 2 cases
by: Tianying Ma, et al.
Published: (2025-01-01) -
Multiple Brain Abscesses in a Patient with Myasthenia Gravis – a Case Report
by: S. Radzevičiūtė, et al.
Published: (2023-12-01) -
Case report: Successful perioperative intervention with efgartigimod in a patient in myasthenic crisis
by: Shahar Shelly
Published: (2025-01-01) -
Ocular myasthenia
by: J. Zakaravičiūtė, et al.
Published: (2022-09-01) -
Inebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review
by: Xiaoqian Song, et al.
Published: (2025-01-01)